B.Riley Financial Maintains X4 Pharmaceuticals(XFOR.US) With Hold Rating, Cuts Target Price to $0.5
B. Riley Adjusts X4 Pharmaceuticals Price Target to $0.50 From $1, Maintains Neutral Rating
X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Stifel Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $4
X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler
Buy Rating Affirmed on X4 Pharmaceuticals: A Comprehensive Analysis of Financial Stability and Drug Development Progress
X4 Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $5 Price Target
X4 Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on X4 Pharmaceuticals, Maintains $5 Price Target
X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler
Optimistic Buy Rating for X4 Pharmaceuticals Following FDA Approval and Strong Clinical Prospects
X4 Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $5
Buy Rating Affirmed for X4 Pharmaceuticals' Xolremdi on Robust Clinical Efficacy and Favorable Market Strategy
X4 Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $3 Price Target
Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects
B. Riley Securities Downgrades X4 Pharmaceuticals to Neutral, Lowers Price Target to $1
X4 Pharmaceuticals Analyst Ratings
No Data